focus -WSS

focus

author：Wikipedia 2025-10-01 01:58:49 Page View：7535

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approves RSV monoclonal antibody for infants, toddlers
Next article： After affirmative action ruling, medical educators look to 'holistic review'

knowledge

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

Key House panel plots a new health care package

CommitteechairmanRep.JasonSmith(R-Mo.)speakswithrankingmemberRep.RichardNeal(D-Mass.).DrewAngerer/Ge

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

Flagship, Pfizer team up in deal worth up to $7 billion

PaulBiondiFlagshipPharmagiantPfizeristurningtoventurefirmFlagshipfornewdrugdevelopment,signingadealw

focus

explore

knowledge

Flagship, Pfizer team up in deal worth up to $7 billion